5/8
08:29 am
dtil
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement [Yahoo! Finance]
Low
Report
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement [Yahoo! Finance]
5/8
08:15 am
dtil
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
High
Report
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
5/7
04:30 pm
dtil
Precision BioSciences to Report First Quarter Results on May 13, 2024
Medium
Report
Precision BioSciences to Report First Quarter Results on May 13, 2024
5/7
08:49 am
dtil
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency [Yahoo! Finance]
Low
Report
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency [Yahoo! Finance]
5/7
08:37 am
dtil
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency [Yahoo! Finance]
High
Report
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency [Yahoo! Finance]
5/7
08:30 am
dtil
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Medium
Report
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
5/7
08:00 am
dtil
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Medium
Report
iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
5/1
07:25 am
dtil
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024 [Yahoo! Finance]
Low
Report
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024 [Yahoo! Finance]
5/1
07:05 am
dtil
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
Low
Report
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
4/30
07:15 am
dtil
Precision BioSciences, Inc. (NASDAQ: DTIL) is now covered by analysts at Guggenheim. They set a "buy" rating and a $19.00 price target on the stock.
Medium
Report
Precision BioSciences, Inc. (NASDAQ: DTIL) is now covered by analysts at Guggenheim. They set a "buy" rating and a $19.00 price target on the stock.
4/16
04:29 pm
dtil
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics [Yahoo! Finance]
Medium
Report
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics [Yahoo! Finance]
4/16
04:15 pm
dtil
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
Medium
Report
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
4/11
11:41 am
dtil
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy? [Yahoo! Finance]
Medium
Report
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy? [Yahoo! Finance]
4/4
11:13 am
dtil
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S. [Yahoo! Finance]
Low
Report
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S. [Yahoo! Finance]
4/4
11:00 am
dtil
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
Medium
Report
iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
4/2
12:02 pm
dtil
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know [Yahoo! Finance]
Low
Report
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know [Yahoo! Finance]
3/27
06:54 am
dtil
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/27
06:45 am
dtil
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
Low
Report
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
3/20
04:39 pm
dtil
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 [Yahoo! Finance]
Low
Report
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 [Yahoo! Finance]
3/20
04:30 pm
dtil
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
Low
Report
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
3/19
07:06 am
dtil
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy [Yahoo! Finance]
Neutral
Report
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy [Yahoo! Finance]
3/19
07:00 am
dtil
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
Low
Report
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
3/6
08:58 am
dtil
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency [Yahoo! Finance]
Low
Report
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency [Yahoo! Finance]
3/6
08:45 am
dtil
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
Low
Report
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
3/6
08:25 am
dtil
iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506 [Yahoo! Finance]
Low
Report
iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506 [Yahoo! Finance]